Replies to post #247123 on Biotech Values

[DewDiligence]

RAIN shelves Milademetan program—reduces workforce 65%:

https://www.globenewswire.com/news-release/2023/05/30/2678353/0/en/Rain-Oncology-Provides-Company-Update-and-Outlines-Strategic-Priorities-of-Milademetan-Clinical-Programs.html

RAIN is now a shell company with a decent amount of cash and a deeply negative enterprise value, which makes it an attractive candidate for a reverse-merger.